Drugs / MSC-IFNα
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT05699811 | Feb 2023 → Dec 2025 overdue | — | Chinese PLA General Hospital | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | MSC-IFNα | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05699811 ↗ |
| Modality | Cell therapy | “genetically express IFNα in bone marrow-derived MSCs” NCT05699811 ↗ |
| Route | Intravenous | “MSC-IFNα form a dose of 2×10\^6 cells/kg, intravenous infusion every 4-6 weeks” NCT05699811 ↗ |